
    
      The primary objective of the study is to determine the safety and tolerability of CC-122
      administered orally in combination with sorafenib, and to define the non-tolerated dose
      (NTD), the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D).

      The secondary objective of the study is to determine the preliminary efficacy of CC-122 in
      combination with sorafenib, based on response Evaluation Criteria in Solid Tumors (RECIST
      1.1)
    
  